GlaxoSmithKline plc and Adaptimmune Therapeutics plc have announced the transition of the development programme for GSK3377794 (GSK ‘794), an NY-ESO SPEAR T-cell therapy, to GSK. Dr. Hal Barron, president R&D, GSK said, “The data we’ve seen for GSK …